ImmunoBiochem Enters Multi-Target License And Option Agreement With ImmunoGen To Develop Next-Generation Antibody-Drug Conjugates
Portfolio Pulse from Benzinga Newsdesk
ImmunoBiochem has entered into a multi-target license and option agreement with ImmunoGen. As part of the agreement, ImmunoGen will pay ImmunoBiochem an upfront fee for an exclusive license to existing antibodies. ImmunoBiochem will be eligible to receive milestone payments and royalties based on the achievement of pre-specified development, regulatory, and commercial milestones.
July 24, 2023 | 10:35 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ImmunoGen's agreement with ImmunoBiochem could potentially lead to financial obligations in the form of upfront fees, milestone payments, and royalties. This could impact ImmunoGen's short-term financial position.
The agreement with ImmunoBiochem involves an upfront payment from ImmunoGen, as well as potential milestone payments and royalties. This could lead to increased financial obligations for ImmunoGen, potentially impacting its short-term financial position and stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100